💼 Just – Evotec Biologics will develop an accelerated solution for monoclonal antibody development and manufacturing.
💲 The program is valued up to $39 million and aims to enhance the DOD’s rapid response capabilities for biologics medical countermeasures.
🔬 The focus will be on decreasing development time, improving efficiency, and ensuring high-quality monoclonal antibodies.
✅ Just – Evotec Biologics’ solution will integrate into the DOD’s rapid emergency response system, with a 100-day target timeline.
Introduction:
The U.S. Department of Defense (DOD) has selected Just – Evotec Biologics to develop an accelerated monoclonal antibody development and manufacturing solution for its manufacturing optimization program. This multi-year program award, valued at up to $39 million, aims to enhance the DOD’s rapid response capabilities for biologics medical countermeasures (MCMs).
- Just – Evotec Biologics will focus on developing and testing process optimization, improving efficiencies in manufacturing, and enhancing operational and resource workflows.
- The company aims to significantly decrease the time for development, manufacturing, and regulatory efforts while maintaining high antibody quality and safety standards.
- The program will culminate in testing the optimized system components through rapid response exercises, starting with a DOD-identified MCM antibody sequence.
- The goal is to integrate Just – Evotec Biologics’ manufacturing solution into the DOD’s rapid emergency response system, with a target timeline of 100 calendar days for advancing drug development from pathogen identification to fielding of doses.
- The collaboration between Just – Evotec Biologics and the DOD aims to ensure rapid development of high-quality and cost-efficient monoclonal antibodies for biologic threats.
Conclusion:
Just – Evotec Biologics has been selected by the DOD to develop an accelerated monoclonal antibody development and manufacturing solution. The program aims to enhance the DOD’s rapid response capabilities for biologics medical countermeasures by significantly decreasing the time for development, manufacturing, and regulatory efforts. This collaboration will contribute to the rapid development of high-quality monoclonal antibodies to effectively respond to biologic threats.
